English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, March 4, 2021
エーザイ、健康経営優良法人2021~ホワイト500~に認定
エーザイ、新型コロナウイルス感染症のケニアにおける検査体制の構築を支援
Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya
Tuesday, March 2, 2021
エーザイ、自社創製の新規不眠症治療薬「DAYVIGO(R)」(一般名:レンボレキサント)について香港において新薬承認を取得
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong
Monday, February 22, 2021
Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090
エーザイ、新規線維芽細胞増殖因子(FGF)受容体選択的チロシンキナーゼ阻害剤E7090が日本においてFGFR2融合遺伝子を有する切除不能な胆道がんを予定される効能・効果として厚生労働省より希少疾病用医薬品に指定
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy
エーザイ、ヒューマン・ヘルスケア理念実現に向けた取り組みについて「企業フィランソロピー大賞」を受賞
Monday, February 15, 2021
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575